Phase II DMSO Trial for Uncontrollable Intracranial Hypertension

  • Lawrence F. Marshall
  • Perry E. Camp
  • Sharon A. Bowers


Dimethyl-sulfoxide (DMSO) has received considerable attention for the treatment of a number of diseases of the Central Nervous System, including stroke, experimental head injury and spinal cord injury3,4,5,6. investigations into the intracranial pressure (ICP) reducing properties of this drug, and its effects on the injured brain, have been carried out over the last decade. De la Torre and his colleagues demonstrated in a primate brain injury model that ICP fell over a few minutes following the infusion of a 40 percent solution of DMSO4. Brown et al, showed in a missile model of penetrating head injury that DMSO improved cerebral perfusion pressure, cerebral blood flow and oxidative metabolism when compared to controls1. In a more recent abstract, Waller et al, reported that DMSO improved the control of ICP and potentially improved outcome in a series of patients suffering coma from acute severe head injury or from subarachnoid hemorrhage9. in a more recent publication, de la Torre et al, showed that doses of up to 4 g/kg/ day were well tolerated in primates with no evidence of long term toxicity7. This confirmed his previous observation that doses of up to 8 g/kg/day could be used without difficulty.


Intracranial Hypertension Cerebral Perfusion Pressure Fluid Overload Spinal Cord Injury1 Acute Subdural Hematoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brown FD, Johns LM, Mullan S: Dimethyl sulfoxide in experimental brain injury with comparison to mannitol. J Neurosurg 53: 58–62 (1980).CrossRefGoogle Scholar
  2. 2.
    Camp PE, James HE, Werner R: Acute dimethyl sulfoxide in experimental brain edema, Part I; effects on intracranial pressure, blood pressure, central venous pressure, brain water and electrolyte content. Neurosurgery 9(1) 28–33 (1981).CrossRefGoogle Scholar
  3. 3.
    Mullan S, de la Torre JC, Kajihara K, Kawanaga HM: Use of dimethyl sulfoxide in experimental head and spinal cord injuries. J Neurol Neurosurg Pshychiat 36: 153–154 (1973).Google Scholar
  4. 4.
    De la Torre JC, Rowed DW, Kawanaga HM, Mullan S: Dimethyl Sulfoxide in the treatment of experimental brain compression. J Neurosurgery 38: 345–354F (March, 1973).CrossRefGoogle Scholar
  5. 5.
    De la Torre JC, Johnson CM, Goode DJ, Mullan S: Pharmacological treatment and evaluation of permanent spinal cord trauma. Neurology 25: 504–514 (1975).Google Scholar
  6. 6.
    De la Torre JC, Kawanaga HM, Rowed DW, Mullan S: Dimethyl sulfoxide in central nervous system trauma. Ann. N Y Acad Sci, 243: 362–389 (1975).CrossRefGoogle Scholar
  7. 7.
    De la Torre JC, Surgeon JW, Ernest T, Wollman R: Subacute toxicity of intravenous dimethyl sulfoxide in rhesus monkeys. The Journal of Toxicology and Environmental Health. 7: 49–57 (1981).CrossRefGoogle Scholar
  8. 8.
    Tsuruda J, Camp PE, James HE, Werner R: Acute dimethyl sulfoxide therapy in experimental brain edema; dose and concentration response on intracranial pressure. Part II. Neurosurgery 10(3) 355–359 (1982).CrossRefGoogle Scholar
  9. 9.
    Waller R, Camp PE, Tanave C, Paxton H: DMSO and neurosurgery. The DMSO Report Vol 1 (1) May (1981).Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Lawrence F. Marshall
  • Perry E. Camp
  • Sharon A. Bowers

There are no affiliations available

Personalised recommendations